Field evaluation of the safety and immunogenicity of a classical swine fever virus E2 subunit vaccine in breeding and nursery animals on Jeju Island, South Korea
10.7774/cevr.2022.11.3.264
- Author:
Guehwan JANG
1
;
Eun-Joo KIM
;
Seong-Cheol CHO
;
Sung-Up MOON
;
Byeong Soo KIM
;
Jinhee KIM
;
Kyoung Ju JEONG
;
Kyungok SONG
;
Seong Hwan MUN
;
Won-Myoung KANG
;
Jonghoo LEE
;
Changnam PARK
;
Hyoung-Seok YANG
;
Changhee LEE
Author Information
1. College of Veterinary Medicine and Virus Vaccine Research Center, Gyeongsang National University, Jinju, Korea
- Publication Type:Original article
- From:Clinical and Experimental Vaccine Research
2022;11(3):264-273
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Classical swine fever (CSF) reemerged on CSF-free Jeju Island where vaccination is not practiced by the unintentional injection of a live attenuated vaccine (modified live attenuated vaccines–low-virulence Miyagi [MLV-LOM]) in 2014. Since the Jeju provincial authority is considering adopting a voluntary immunization policy using a CSF-E2 subunit vaccine to combat LOM-derived CSF endemic, this study aimed to evaluate in Jeju herds.
Materials and Methods:Two vaccination trials using the Bayovac CSF-E2 vaccine licensed for use in South Korea assessed the safety and humoral immunity of the CSF-E2 vaccine in breeding (trial 1) and nursery animals (trial 2) under farm application conditions.
Results:Neither local nor systemic (including reproductive) adverse effects were objectively observed in pregnant sows and young piglets following a respective vaccination regime at pregnancy or weaning, respectively. Trial 1 showed that sows immunized with the CSF-E2 vaccine possessed high and consistent E2-specific and neutralizing antibody levels. The CSF-E2 vaccine-immunized pregnant sows subsequently conferred appropriate and steady passive immunity to their offspring. In trial 2, a double immunization scheme of the CSF-E2 vaccine in piglets at 40 and 60 days of age could elicit a consistent and long-lasting adequate antibody response. Additionally, the two trials detected no E rns -specific antibody responses, indicating that CSF-E2 vaccine can differentiate infected from vaccinated animals (DIVA).
Conclusion:Our trial data collectively provide invaluable information on applying the CSFE2 subunit vaccine to circumvent the possible drawbacks associated with the MLV-LOM concerning the safety, efficacy, and DIVA, in the LOM-endemic field farms and contribute to advanced CSF eradication on Jeju Island.
